• I interviewed and was verbally offered a position in September 2022. However, due to delays and restructuring, I am currently exploring other opportunities. • During this break, I studied developments in immuno-oncology, machine learning, volunteered, and supported family needs

• Analyzed proprietary and public data sets to characterize sensitivity and resistance of compounds across cancer cell lines• Informed decision-making through examination of clinical responses in bladder cancer trials, sub-classifying response data using clinical RNA-seq data• Planned central transfer of clinical and pre-clinical data to data lake for future intelligent queries and machine learning

• Mined genomic datasets for gene signatures of inflammation• Predicted sensitivity to knockout of target genes using multi-omic datasets• Collaborated with vendors to obtain tumor models for pharmacology experiments

• Conducted literature review for variant collapsing to increase power in genome-wide, phenome-wide, and exposome-wide association studies (GWAS, PheWAS, ExWAS)• Re-annotated variants in a UK Biobank study of 281,000 whole exomes using proprietary variant calling algorithms• Developed methods for mapping traits to genes using R and Python in Illumina’s Genome Research Environment

• Personal break during this period due to a series of unfortunate events.• During this time, I faced several challenges that required my attention and care. I had a serious bicycle accident just days before the "shelter in place" mandate during the COVID-19 pandemic, resulting in injuries that included significant damage to my face, the loss of three upper front teeth, and the shearing off of my lower lip. The timing of the accident coincided with the shutdown of cosmetic dentistry services, which delayed my recovery as I awaited crowns for dental restoration.• In addition to these challenges, I experienced unexpected acute health issues stemming from a situation in 2017, which led to undergoing two major surgeries and being hospitalized for an entire month. Unfortunately, in a separate incident in May of 2019, I suffered a severe concussion in a car accident, leading to another brief hospitalization.• Throughout this break, I used the time to focus on recovery and to spend valuable moments with my mother, who had been battling a neuroendocrine tumor originating from her kidney for over two decades. Her condition worsened during this period, and I was fortunate to be able to provide her with care and support in her final days.• During this time, I was approached by two former colleagues who sought my expertise in bioinformatics. I undertook consulting roles for two companies: 858 Therapeutics for a year and Illumina Emerging Solutions for six months, as detailed in the descriptions provided earlier. These consulting engagements allowed me to contribute my skills and maintain a connection with the field despite the circumstances.

• Investigated and benchmarked computational tools including Seurat, totalVI, and scVI (total and single-cell variational inference using deep neural networks) for single-cell CITE-seq data analysis to integrate RNA and surface protein measurements to look for latent structure.• Built custom sequence processing pipelines for bulk and single-cell experiments.

• Collaborated in building network and sequence analysis pipelines for internal sequencing facility.• Evaluated drug resistance mechanisms of Abraxane for pancreatic cancer using single-cell analysis.• Developed workflows to process genomic data types (CITE-seq, RNA-seq, etc.) from single-cell sequencing.• Supported creation of genomic library resource for patient-derived models.• Democratized data consumption for multi-omics data in a multiple-myeloma consortium through working with an external vendor.

• Analyzed gene expression and chromatin state data from various models, enabling development candidate compounds (IND filings).• Identified biomarkers for compounds targeting epigenetic modulators.• Created gene panels monitored in patients for first-in-human clinical trials.• Developed cloud pipelines in AWS for a broad range of bulk and single-cell multi-omic experiments.

• Developed interactive web app using R and Shiny for the tracking, visualization, and analysis of qPCR data from the Fluidigm BioMarkHD.• Characterized the inhibition of BRD4 on GBM and triple-negative breast cancer models.• Demonstrated LSD1 inhibitor's impact on leukemic stem cells.• Characterized genomic features and performed molecular subtyping of a large array of tumor models.

• Provided technical support and advice for experimental design for whole-genome sequencing as a service.• Managed storage and encrypted delivery of customer genomes using AWS.• Wrote documentation, tutorials, and software tools while managing online user community.

• Led investigation of biology of fear, learning, and memory in rodents using an integrative systems genetics approach.• Mentored graduate and rotating students in R programming and statistics.• Regularly presented work and moderated discussions at journal clubs and meetings.

2008 UCLA Dissertation Year FellowPioneered work investigating role of DNA copy number on transcription of genes in mammalian cell lines. Modeled the structural genetic changes (duplication, inversion, and deletion) that occur in cancer on a genome-wide scale in a mammalian cell culture system. The system provides predictive value in manipulating signal transduction pathways.

• Administered labs and discussion sections for two groups of 18 students.• Composed exam questions, conducted review sessions, administered, and graded exams.• Led two classes consisting of 280 and 180 students.

• Managed high throughput DNA sequencing core.• Improved sequence throughput by a factor of four by streamlining DNA template purification protocols.• Integrated new sequencing instruments into workflow including ABI 3100 capillary sequencer.• Developed nucleic acid purification technologies with partner company GeneMachines.• Played central role in automating large-scale genetic screen using robotic pipetting platforms.• Presented departmental progress reports at company status meetings.• Interviewed, hired, and supervised lab assistants and student interns.

• Led a group in optimizing DNA purification technologies for production DNA sequencing.• Integrated seven ABI 3700 analyzers into workflow and wrote in-house protocols.• Tested prototypes of high throughput DNA template purification robot with partner company GeneMachines.• Developed laboratory information management systems, educated users across sites in South San Francisco, Portland, and Germany.• Served as chief point of contact for small sequencing projects, held seminars on emerging technologies.

• Integrated new sequencing instruments into workflow including the ABI 3700 and 3100 capillary sequencers and magnetic bead-based DNA preparation increasing throughput by a factor of four.• Played central role in automating large-scale genetic screens in D. rerio, C. elegans, and D. melanogaster using robotic pipetting platforms.